Compare Enveric Biosciences Inc (ENVB) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Microchip Technology Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Microchip Technology Inc. trades at $76.45 (market cap $42.37B). The key difference: Microchip Technology Inc. is far larger — about 6333.3× Enveric Biosciences Inc's market cap, and Microchip Technology Inc. pays a 2.33% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Microchip Technology Inc. for 62 Days on average.
| ENVB | MCHP | |
|---|---|---|
Market Cap | $6.69M | $42.37B |
Volume | 41,141 | 8,887,625 |
Sector | Health | Technology |
52-Week High | $10.80 | $102.97 |
52-Week Low | $1.27 | $49.02 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | -$1.60M | $47.49B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
MCHP trades at $75.52, down 7.06% over 24 hours amid a bearish technical signal. The company reported a net loss of -$500K for 2025, though it has beaten EPS estimates for the last three quarters. Analyst consensus is strongly bullish with a $110.50 price target, and recent news highlights expansion in Ethernet and 48V power portfolios, plus the completed acquisition of Hailo to bolster edge AI capabilities.
The outlook is mixed: strong analyst support and strategic acquisitions in growth areas like AI and data centers present upside, but high valuation ratios, significant debt, and recent profitability challenges pose risks. The stock's near-term performance will hinge on Q3 2026 earnings and execution in high-demand semiconductor segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
